Transamniotic Fetal Delivery of Recombinant Human Immunoglobulin Monoclonal Antibodies: A Potential Novel Strategy for Prevention of Neonatal Respiratory Syncytial Virus (RSV) Disease
Topic overview
This study explores transamniotic fetal immunotherapy (TRAFIT) as a novel prenatal delivery method for RSV-specific monoclonal antibodies, aiming to provide passive immunity against respiratory syncytial virus before birth. Researchers investigated whether therapeutic IgG administered to the fetus in utero maintains protective levels after delivery, potentially offering a preventive strategy for high-risk newborns.
Key takeaways
- Modified monoclonal IgG antibodies can protect infants from RSV, which causes high morbidity in newborns.
- Transamniotic fetal immunotherapy (TRAFIT) may enable prenatal delivery of anti-RSV monoclonal antibodies to the fetus.
- Study investigates whether prenatally delivered anti-RSV IgG remains bioavailable after birth for neonatal protection.
- Novel prenatal immunization strategy could prevent RSV disease in high-risk newborns before postnatal exposure.
Keywords
Hashtags
Full article text
Full article text not available for this entry
How to cite: GlobalCastMD. Transamniotic Fetal Delivery of Recombinant Human Immunoglobulin Monoclonal Antibodies: A Potential Novel Strategy for Prevention of Neonatal Respiratory Syncytial Virus (RSV) Disease. GlobalCastMD Medical Library. 2025-08-08. https://dev.library.globalcastmd.com/article/10790?via_space=staycurrentmd
Comments